Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Alan Newman who wrote (6378)	4/12/1999 11:13:00 AM
From: Linda Kaplan	Respond to of 7041

A stockbroker called me and read me the releases. I don't have a link. I'll see if I can get one later. Linda

To: Alan Newman who wrote (6378)	4/12/1999 11:48:00 AM
From: Linda Kaplan	Read Replies (1) \| Respond to of 7041

Oppenheimer issues these reports to their customers first. It won't be publicly circulated for about a week. However, the analysis was prepared by matt geller, and he can be reached at the following number: 212 667 7034. You might be able to get him to fax you a copy of the report. Here are more details from it: He met with ZONA on the 6th and says he maintains his expectectations for a mid 4th quarter global launch, but cut numbers dramatically. There was a table and there was text. The table and text were contradictory. The prior expectations for 1999 were .93, and the new, according to table is .19, and new according to text is .21. That's a drop from .93 to .19 or .21. The prior expectations for 2000 were .74 goes to .40 in table and in text .41. Exectations for 2000 thus reduce from .74 to either .40 or .41. The prior expectations for 2001 were 1.33 and were reduced to 1.29 both text and table. Vasomax revenue had been estimated for 1999 to be 31 million dollars based on end user vasomax sales and was cut to 9.7 million. That is revenue not income -- what the drug stores take in, not what zona takes in. ZONA gets maybe 20% of the wholesale price not 100% of retail. We don't know exactly what their percentage is, but I'm assuming 20% of wholesale. I made an error in the prior note, saying July instead of June. The FDA meeting is to be June 2,3 and 4th not July. Vasomax is NOT on the schedule for the June meeting and the next meeting takes place in September. That means, assuming that approval or disapproval would only take place after such a meeting, (and that's generally considered to be the case) that no decision will be made by the FDA about Vasomax until at least September. Linda